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Division of Dermatology (D Kl . GG K L University of Uta h College of M edicine. and Department." of M edicine 
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Percutaneous absorption of dexamethasone a nd its effect on t he pituitary adrenal axis were 
measured in vivo in norm al human subjects afte r a ppli cation to skin . Specific plasma 
dexamethasone and corti sol radioimmunoassays were used . Following application of 1 ~ 
dexamet.hasone on 500 em 2 of normal skin , the pla sma dexamet.hasone conce ntration was 
maximal at 2 hr. a nd the average absorption was O.25 g( over 8 hr ; sign ificant cortisol 
su ppression occurred at 2. 4. and 8 hr. This technique: (1) provides an accu rate assessment of 
the in vivo absorpti on of dexamet.hasone applied to human skin. (2, avoids exposure of the 
subjects to radioact ive steroids. (3) perm it.s estimation of t he Quantity of unmetabolized 
steroids absorbed. and (4) serves as a possible model for the development of similar assays for 
other topical steroids. 
Altbough there a re limited data on the quantity 
and patt.ern of t heir absorpt.ion, topical corti coste-
roids enjoy widespread use in clinical medicine. 
Previous stud ies of t.opi cal absorption utilized in 
vitro skin prepa rat ions Ill. topically applied radio-
actively labeled corti costeroids 12-41. and physi o-
logic changes 15-6/. These studies were limited by 
the inability to d irectly measure plasma leve ls of 
the applied steroid. 
The objective of thi s study was to use specific 
radioimmu noassays t.o Quantitate the percutane-
ous absorption of dexamethasone and to det.ermine 
the effect of the absorbed dexamethasone on the 
adrenal- pituitary axis. 
MATERIALS ASD METHODS 
Three normal males and one normal female. ag-es 22 to 
28. participated in the study and se rved as their ov.'Tl 
con trols. Three days before the dexamethasone study, 
baseline plasma cort isol concentrations were determ ined 
from samples drawn at O. L 4. 12 • 1, 2. 4. and 8 hr. 
beginning at 8 AM. T o insure initial uniform hydration on 
t he days that dexamethasone was applied. the applies -
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Abbreviations: 
lADe: integrated average dexa methasone concen· 
tration 
MRC: melabolic clearance ra te 
T .... : half lime 
~li6 
tion sites on the subjects' bacb were occluded with 
plastic film fo r 1 hr . After the occlusive wrap was 
removed. the excess moisLU re was patted dry with a paper 
towel and 1 ml of a standard solu t.i on of 10/, dexametha · 
sone in acetone was applied per 100 em ' (100 JJg /c m 7 ). A 
single ap pl ica tion of the 11ft dexamethasone solution was 
made at weekly intervals on areas of 100. 200. and 500 
em' in the same Breas on each subjec t. The dexametha· 
sone was applied wi th a mechanical pipett e (Selec· 
lapette) and a " T " shaped glass rod was w:;ed to 
distribute the solution evenly. The acetone evaporated 
rapidly. leaving a light coat of white crystals on the skin . 
Following the application of the dexametha!'One. the 
application sites were not re ·occludcd and there were no 
efforts to guard them . Blood was collected al the same 
times as in the control period and was assayed for 
dexamethasone and cort isol. 
One week afte r the last topical study. the distribution 
and plasma kinetics of dexamethasone were determined 
by injecting 1.2 mg of dexamethasone phosphate (I mg of 
dexamethasone) intravenously at 8 AM and obtaining 
serial plasma samples at I,Ib. I ~ , 1 2 • I. 2. 4. 6. and 8 hr. 
T he lwo·companment model ofTait et 81 [7] was u!o;ed to 
calculate the metabolic clearance rale (Me R), the 
plasma half time rr .... ) of elim ination. and the volumes of 
di str ibution VIand V 2' The fra ction of dexamethasone 
a bsorbed percutaneously was ca lculated usi ng the foll ow. 
ing formula : 
IADC x (MC'R/3J Percent absorbed /8 hr ;. ,01. 100 
dose applied (mg) 
(lADC ~ int.egrated average dexamethasone concentra · 
tion) . 
Specific antisera were prepared fo r dexamethasone 
and corti sol by imm un izing rabbits with steroid ·bovine 
seru m albumi n conjugates. T he methodology of the 
deve lopment of the assays has been described previously 
IS-tO). The dexamethasone assay has a sensitivity of 10 
pg/assay tube and is specific for unmetabolized dexa· 
melhasone (to I. Of the known endogenous steroids. only 
cortisol cross· reacted significantly , O .4 ~. Because of this 
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cross reaction, a smaJI amount of radioactive dexametha-
sone was added to each sample as an internal recovery 
standard, and the dexamethasone was isolated by paper 
chromatography before being assayed lID). AU va.lues 
were corrected for the losses inherent in the extraction 
and chromatography procedures. 
RESULTS 
After application of 1 ml of 1 % dexamethasone 
to 100 crn 2, the plasma dexamethasone levels were 
less than 20 ng/dl , and after application of 2.5 ml 
to 250 cm' they were from 20- 40 ng/dJ. Accord-
ingly, the corresponding plasma cortisol levels were 
not suppressed (Fig. I) . 
The mean peak plasma dexamethasone concen-
tration, following application of 5 ml of 1 % dexa-
methasone on 500 cm " was 250 ± 90 ng/ dl and 
occurred at about 2 hI. This decreased over the 
next 6 hr to 90 ng/ dl (Fig. 2). Figure 1 shows the 
average plasma cortisol levels during the control 
period and the values after application of 1% 
dexamethasone on 100, 250, and 500 em'. Although 
the initial cortisol levels of the control were higher 
than expected! they were reproducible. Further, 
the values of the lOO·cm' and 250-cm2 experiments 
reveal that all the zeTO time values aTe closely 
grouped. There was no significant difference be-
tween the cortisol values for the four trials at times 
0, J 4 , J 2 , and 1 hr. Cortisol suppression was 
significant (p < 0.05, paired t-test ) at 2.4, and 8 hr 
after application of 1 % dexamethasone on 500 em 2 , 
The Table summarizes the individual and aver-
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FIG. I. Mean plasma cor tisol levels before and after 
application of 1% dexamethasone on 100, 250. and 500 
em '. For clarity SEM is indicated for only the control and 
the 500 ern 2 trial. Significant suppression (p < 0.05) was 
present at 2. 4. and 8 hr afte r the application of 1 % dexa-
methasone on 500 cm!. 
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FIG . 2. Plasma concentration of dexamethasone after 
the application of 5 ml of a 1 ~ solution on 500 em 2. mean 
± SEM . 
TABLE. Dexamethasone kinetics and percutaneous 
absorpt ion 
T. Me R 
,; 
Subjects Arn.orption/S ( m m)a (lilersl24 hr )G h,' 
V. Z. 280 225 0.35 
G.H . 260 256 0.10 
K . L. 180 504 0.34 
S. W. 235 275 0.21 
Mean ± SEM 238 ± 22 3 15 ± 64 0.25 ::r .06 
a Kinetic measurements determined following the in-
t ra venous inject ion of 1.2 mg of dexamethasone phos-
phate. 
LADC x (MCR/3) 
tI Percent absorbed/8 hr = x 100. 
dose applied (mg) 
age \'alues for the plasma T " . metabolic c learance 
rate, and the percentage absorbed over 8 hr. 
DISCUSSION 
Using specific radioimmunoassays. it was possi -
ble to quantitate the percentage of unrnetabolized 
dexamethasone absorbed , the a bsorption pattern 
of dexamethasone through normal human skin in 
vivo, and the effect of dexamethasone absorption 
on the pituitary- adrenal axis. 
Alt.hough the initial hydration of the skin was 
constant, considerable absorption variation was 
noted among subjects. This is consistent with 
previous sl.udies 12-3 J and implies that the effec-
tive dosage range may vary greatly among pa -
tients. 
Our data corroborate the study of Feldman and 
Maibach [2J. who applied 4 Jlg/ cm' of " C-Iabeled 
dexamethasone to 98 cm' on the forearms of 
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normal volunteers and measured the excretion of 
radioactivi ty in the urine . They found that the 
radioactivity of the urine was maximal in the first 
12 hr, 0.096% of the applied dose . Apparent differ· 
ences in absorption (0.25%/8 hr in this study vs 
0.096%/12 hr) may result from differences in proce· 
dures and characteristics of the respective assays. 
By preoccluding the application areas, the hydra . 
tion of the skin was increased , possibly allowing for 
a more rapid and increased absorption. Theoreti-
cally. if the preocclusion had significantly affected 
the Smount and pattern of absorption. we would 
expect to see a more uniform response. Some of 
these apparent discrepancies might also be ex -
plained by differences in experimentsl techniques 
used to quantitate absorption . With our assay we 
were able to determine plasma levels of the unme-
tabolized dexamethasone at specified frequent in-
tervals. The measurement of radioactivi ty of the 
urine using the techniques described by Feldman 
and Maibach 13J did not specifically measure 
unrnetabolized dexamethasone . 
Following large doses of topical corticosteroids to 
normal unoccluded skin, minimal effects on cor-
tisol secretion have been observed IB]. Using spe-
cific radioimmunoassays and applying 50 mg of 
dexamethasone to normal skin , we were able to 
correlate dexamethasone and cortisol levels and 
show suppression at 2. 4. and 8 hr . In previous 
Hudies. 24-hr urinary 17-0H cort icosteroids were 
measured after the administrat ion of topical cor ti-
costeroids ; consequently. transient suppressive ef· 
fects may have been undetected . We would expect 
greater absorption with diseased skin. along with a 
corresponding increase in suppression of the pitui -
tary-adrenal axis [6-11]. 
No sa mples were collected prior to 15 min and 
although the lower limit of the assay is 25 ng/d!. 
the value at 15 min implies a small amount of 
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absorption . Subsequent to this time more rapid 
absorption is seen. 
The advantages of a plasma assay that is both 
sensitive and specific are obvious. The technique 
described provides an accurate assessment of the 
in vivo absorption of dexamethasone applied to 
human skin . It does not require exposure of the 
subjects to radioactive steroids, it permits est.ima -
tion of the quantity of unmetabolized steroids 
absorbed, and it is a model for the development of 
similar assays using other topical steroids. 
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